Therefore, the crosstalk between the Exo hsa_circ_0050334-hsa_miR_182_5p-RGS2 axis and tumor-infiltrating immune cells in CRC, provides a potential therapeutic target for future treatments of CRC. Here, RGS2 is linked to neoplasm.